FIELD: medicine, pharmaceutics.
SUBSTANCE: present invention refers to aryl- and heteroarylsubstituted diasaspiropyridine derivatives of formula (I) 
to its pharmaceutically acceptable acid- or base-additive salt wherein A represents a radical of formula (II) 
wherein each k, l, m, n independently represents an integer equal to 0, 1, 2, 3 or 4, provided (k+1) and (m+n) are equal to 2, 3, 4 or 5; wherein one of -CH2-fragments can be substituted by atom O; and wherein one of -CH2-fragments can be substituted by an oxo group; X represents CH or N; R3 is specified in a group consisting of hydrogen, C1-5alkyl and C3-6cycloalkyl; each R4, R5 is independently specified in a group including hydrogen, halogen, oxo, C1-3alkyl and C1-3alkyloxy; p represents an integer equal to zero, 1, 2 or 3; q represents an integer equal to zero, 1, 2 or 3; each Y1, Y3, is independently specified in a group including a single bond and O; Y2 represents saturated or unsaturated C1-6hydrocarbon radical with a straight chain; B is specified in a group including phenyl optionally substituted by the number of the substitutes R6 each of which is independently specified in halogen; and wherein r represents an integer equal to zero, 1 or 2; alkyl represents a saturated hydrocarbon radical with a straight and branched chain containing said number of carbon atoms; wherein said radical can be optionally substituted by one or more carbon atoms or more radicals specified in a group including halogen, cyano, hydroxy, amino, oxo, carboxyl, nitro, thio and formyl; and halogen represents fluorine, chlorine, bromine or iodine. Also, the invention refers to a pharmaceutical composition based on the compounds of formula I as an active ingredient for preparing a drug for preventing and/or treating mental disorders, including but not limited to anxiety, eating behavior disorder, affective disorders, such as bipolar disorders and depression, psychosis, such as schizophrenia, and sleeping disorders; obesity, diabetes; sexual disorders and neurological disorders; to a method for preparing a pharmaceutical composition, and to using the compounds of formula I for preparing the drug.
EFFECT: there are prepared and described new compounds possessing melanin-concentrating hormone (MCH), particularly MCH-1 antagonist activity.
19 cl, 4 ex, 7 tbl
| Title | Year | Author | Number |
|---|---|---|---|
| 3-AZABICYCLO[3,1,0]HEXYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | 2009 |
|
RU2510396C2 |
| INDOLE AND BENZOXAZINE DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | 2009 |
|
RU2512283C2 |
| 1,2,4-TRIAZOLO[4,3-A]PYRIDINE COMPOUNDS AND USE THEREOF AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2 RECEPTORS | 2015 |
|
RU2695651C2 |
| COMBINATIONS COMPRISING PDE 2 INHIBITORS SUCH AS 1-ARYL-4-METHYL- [1,2,4]TRIAZOLO[4,3-A]QUINOXALINE COMPOUNDS AND PDE 10 INHIBITORS FOR USE IN TREATMENT OF NEUROLOGICAL OR METABOLIC DISORDERS | 2013 |
|
RU2657540C2 |
| INDOLE AND BENZOMORPHOLINE DERIVATIVES AS MODULATOR OF METABOTROPIC GLUTAMATE RECEPTORS | 2009 |
|
RU2517181C2 |
| IMIDAZO[1,2-a]PYRIDINE DERIVATIVES AND THEIR APPLICATION AS POSITIVE ALLOSTERIC MODULATORS OF mGluR2 RECEPTORS | 2008 |
|
RU2492170C2 |
| 6,7-DIHYDROPYRAZOLO[1,5-A]PYRAZINE-4(5H)-ONE COMPOUNDS AND USE THEREOF AS NEGATIVE ALLOSTERIC MODULATORS OF mGluR2 RECEPTORS | 2015 |
|
RU2711382C2 |
| MDM2 AND P53 INTERACTION INHIBITORS | 2007 |
|
RU2436784C2 |
| CONTAINING A SUBSTITUTE, WHICH IS BUTANE, IN THE HETEROCYCLIC RING A PYRIDONE DERIVATIVE FOR TREATING FIBROSIS AND INFLAMMATORY DISEASES | 2017 |
|
RU2738844C2 |
| THIOPHENE COMPOUND, ITS PRODUCTION METHOD AND ITS PHARMACEUTICAL APPLICATION | 2017 |
|
RU2709473C1 |
